[Congressional Record Volume 151, Number 105 (Thursday, July 28, 2005)]
[Senate]
[Pages S9204-S9207]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
STEM CELL LEGISLATION
Mr. KENNEDY. Mr. President, before leaving the floor, if I can have
the attention of our minority leader. Is it the understanding of the
leader in propounding this request that the measures proposed in the
request had bipartisan support in the House of Representatives, and he
believes as I believe--and I see my colleague, the Senator from Iowa,
who is a great leader on this, who believes as well--that there is very
strong bipartisan support for the legislation, and we could, in a
reasonable period of time--really in a matter of hours--pass the
legislation and still not exclude the possibility of continued debate
and discussion on the other measures relating to stem cells; and that
this would permit us to act before August 9, which would be the fourth
year since we had the limitation and restriction on stem cell research,
the kind of research that 80 Nobel laureates in a letter to President
said offers the greatest opportunity for progress in the areas of
Parkinson's disease, juvenile diabetes, cancer, and
[[Page S9205]]
so many other diseases--do I understand the position of the Senator
from Nevada is that he believes the progress taken in the House of
Representatives in a bipartisan way should be given the opportunity for
action in the Senate?
Mr. REID. I say through the Chair to my friend that I believe there
is a significant majority in the Senate that would quickly support both
of these bills. I say that without any hyperbole. I believe without
question that a significant number would vote for this legislation.
Mr. KENNEDY. Is it the position of the Senator from Nevada that this
is the same kind of research that, as I mentioned earlier, Nobel
laureates indicate offers the greatest opportunity for progress in
dealing with the kinds of illnesses and diseases that just about every
family in America in one way or the other is affected by, and he
believes, as I do, that this offers an enormous opportunity for hope
and progress in conquering or curing these diseases?
Mr. REID. Mr. President, I have spoken with scientists, physicians,
people who have diseases, and the families of those who have diseases,
and there is a sparkle of hope and anticipation from the scientific
community, from the people who are ill, and from their loved ones--a
sparkle of hope and opportunity that I have never seen before. There is
the hope that these children, for example, who are stuck with needles
tens of thousands of times in their little lives will no longer have to
have that done; the hope that someone who is beginning Parkinson's
syndrome will be able to be cured. This is hope I have never seen
before.
We need to go forward with this as quickly as possible. That is why
for us in the Senate, a couple of months is not much. For those people
who are sick and the loved ones of those people, it is an eternity. I
can remember Steve Rigalio, an executive at Nevada Power, the largest
power company in Nevada, who got sick with this disease. I personally
watched this man. He had Lou Gehrig's disease. I personally watched
this man deteriorate before my eyes. He was dead in a matter of months.
The average life expectancy from the time the disease is diagnosed is
16 months. That is why the time we spend here is so important and why
we must move forward.
Mr. President, I ask unanimous consent that this time I have taken
this morning be charged to leader time and not to morning business
time.
The ACTING PRESIDENT pro tempore. Is there objection?
Without objection, it is so ordered.
The Senator from Iowa is recognized.
Mr. HARKIN. Mr. President, if I might follow up on the discussion now
on the Senate floor, might I ask the distinguished majority leader a
question. It is this Senator's understanding, and I think the
understanding of others with whom I have spoken, that the distinguished
majority leader, during the last work period--I think that was prior to
the Memorial Day--no, before the Fourth of July break, I guess it was.
It was my understanding that the majority leader had made a commitment
that we would bring up a stem cell bill prior to the August recess. I
may be mistaken. If so, I stand to be corrected.
My question is to the distinguished majority leader, was a commitment
made to bring up the stem cell bill? If so, I am wondering why we have
not done so and why we have waited until 2 days before we leave and we
still don't have a stem cell bill before us?
Mr. FRIST. Mr. President, I appreciate the comments of the Democratic
leader, our colleagues from both Iowa and Massachusetts. It gives me an
opportunity to make it clear. My belief both in the science, the
potential--we have to be careful not to overpromise. I know my
colleagues are aware of that. As a physician, you never overpromise and
give false hope. You have to be very careful. On the other hand, I
understand the huge promise of this science, the proven therapies of
adult stem cells, as well as these magnificent embryonic stem cells.
Unfortunately, the only way you can obtain them is from the destruction
of the blastocyst. That is the ethical issue everybody struggles with.
As majority leader, people come to me all the time and have this
discussion in a very personal way, about the complexities and the
advancing science coming together in a nexus that we are going to
increasingly have to face in this Chamber. Both of my colleagues who
have spoken this morning have been real leaders in that field. I, in
the last 2 months, have said we have a responsibility to come back and
review policy--policy where you have advancing science. You have moral
considerations for each one of us, but that is our responsibility.
As individuals, we have different feelings, but as a body politic,
this body needs to address them. Now, in doing that, I have put on the
table, as leader and in discussions with the Democratic leader for the
last 6 weeks, the opportunity to address the Castle bill, H.R. 810,
which passed the House, and bring it to the Senate floor free of
amendments. The bill is not written very well. It doesn't have the
ethical construct that I believe we absolutely need.
So I think the bill is not ideal. But to give the opportunity to have
a vote on that bill, to give the opportunity to have a vote on the cord
blood bill, which is proven therapy--and cord blood can be used, and
bone marrow transplants are used right now for thousands of people.
That is adult stem cells. Then to address the newer science, which is
too preliminary but gets through a lot of ethical issues--right now, to
get the stem cells, it requires the destruction of the embryo. There is
a science out there that is preliminary but promising, and maybe you
don't have to destroy embryos to get these cells. That really has been
developed in talking to scientists, and that deserves consideration on
the floor as well because it gets beyond all the ethical
considerations.
As we said, let's get clean shots on these three bills so everybody
can express themselves and see where the votes are. Others have come
forward, and my colleague from Kansas says he cannot agree to that, to
giving these bills up-or-down votes on the floor without the
consideration also of another very important bill, and that is the
cloning bill, which is an element a little bit outside of just the
developing embryos and the destruction of embryos. So I put that offer
on the table after discussion with the Democratic leader.
With that, other people have their individual bills. That is why we
are not addressing it right now, because I have not been able to get
unanimous consent to do that. What I hope both of my colleagues and
others recognize is that I believe, as leader, it is an important issue
that has to be addressed by this body. It needs ongoing review, and I
am trying to do just that. I have been denied that by the body thus
far. To bring up a bill and pass it today, which strikes at the moral
and ethical fundamentals of each and every one of us, and try to just
take that single bill--or just two bills through without respecting my
colleagues, I just cannot do that. I look forward to working with both
of my colleagues on this important issue, which I believe needs to be
addressed.
Mr. HARKIN. Will the Senator yield for a question?
The ACTING PRESIDENT pro tempore. The Senator from Iowa controls the
time.
Mr. FRIST. I am happy to respond.
Mr. HARKIN. I thank the majority leader. It is this Senator's
understanding that there have been a number of different bills proposed
to deal with cloning and a number of other issues that don't really
pertain to the issue of embryonic stem cell research as the bill was
passed by the House.
Is it not true, I ask the distinguished majority leader, that H.R.
810--the bill we are talking about that passed the House with a
bipartisan majority and has a number of supporters on both sides of the
aisle in the Senate--has bipartisan support in the Senate? Last year, I
will say in further expanding on my question, I think there were 58
Senators who signed a letter in support of that legislation, many of
the same Senators who are still here. So it has a lot of bipartisan
support. These other bills, we don't know. In fact, I say to the
distinguished majority leader, there are a couple of bills we heard
about but we have never seen any language on.
My question to the majority leader is: Why can't we bring up the bill
that passed the House, which everyone knows about--it is clear, it is
straightforward, it passed the House, as I said,
[[Page S9206]]
with a bipartisan majority, it has bipartisan support here; we all know
it has enough votes to pass probably many more than even 60 votes, I
would venture to guess--why can't we take that up, pass it, get it to
the President, and then when we come back in September, we can take up
these other bills?
I do not have any problem with these other bills coming up. Some I
may support when they come up. To bring them all up together clouds and
confuses the issue. Why can't we just bring up the House bill, simple,
straightforward, have a limited debate on it, and vote it up or down as
they did in the House, I ask my leader?
The ACTING PRESIDENT pro tempore. Without objection, the majority
leader is recognized.
Mr. FRIST. Mr. President, I very much appreciate the question. It
gives me the opportunity to show the work and the challenge it is to
address an issue that strikes at the science and ethical concerns.
My approach has been to include what I think the Senator from Iowa
wants, and that is a clean up-or-down-vote on this bill. I have real
concerns with how that bill is written, and I will give several
examples of why it bothers me a bit the way it is written and passing
as a clean bill. But I am willing to do that if I can take into
consideration the moral concerns and scientific concerns of others in
this body and give them the same opportunity that the Senator from Iowa
is asking for, and, thus, put together a group, a defined group, but
not an unlimited group--we will be voting up or down on all sorts of
votes--but see where everybody is on alternative ways: You do not have
to destroy embryos to get the same cells you get from embryos, the cord
blood bill, H.R. 810, and the cloning bill. It is a separate issue but
involves the creation of embryos and ultimately the destruction of
embryos.
That is what we are talking about. That is my attempt. It is going to
take a while on the floor of the Senate because of the fact of it not
having gone through the committee process and the fact everybody does
stand in little different positions, from an ethical standpoint, on any
of the bills.
On H.R. 810, the consent process is inadequate, from my standpoint.
There is not an ideal ethical construct. It says informed consent, but
it does not specifically talk about the potential for financial
incentives between, say, a physician and an in vitro fertilization
clinic. That is not addressed specifically in the bill. Instead of
voting up or down, I would like to at least discuss those issues.
Another issue--there is informed consent and the financial
incentives--would be if we pass it, it is passed forever; there is no
opportunity to come back and look at it on a periodic basis, say, every
4 or 5 years.
I mention those concerns because I am willing to step back and give a
clean vote on that if we can take into consideration other people's
issues or their particular bills. I am a little surprised my colleagues
have not taken me up on that opportunity, but since they have not, we
will have to come back and figure the best way to address it when we
get back after the recess.
Mr. HARKIN. Mr. President, I thank the majority leader for his
response. I know Senator Kennedy wants time to make a speech. On the
stem cell bill, I say to my friend from Tennessee, the distinguished
leader, the clock is ticking. It does have a lot of support. There may
be a lot of ideas out there. No bill that ever passes here has 100-
percent approval by everybody of every, as they say, ``jot and tittle''
in the bill. If I were to rewrite H.R. 810, I might want to write it
differently myself.
The fact is a lot of thought was given to it. The disease groups that
represent the very ill people in this country--the Juvenile Diabetes
Foundation, Spinal Cord Injury Foundation, and a whole host of other
groups--have put their stamp of approval on this bill. They want it
passed.
It just seems to me that the more we dawdle around here--I understand
we are in the last couple of days. We have been here all of July. This
bill, H.R. 810, has been sitting here. We could have taken it up at any
time. It is this Senator's observation that all of a sudden all these
other bills are popping up on cloning, chimeras, and others, which I am
not saying are not important issues, but they are separate and aside
from this issue.
If the distinguished majority leader wants to bring those up at some
other time for debate and amendments and bring them up for a straight
up-or-down vote, that is fine, I don't have a problem with that, but
don't tie them in with a bill that has strong majority support on both
sides of the aisle, strong bipartisan support, as was shown in the
House, and one which, if passed, could be sent to the President right
away for his signature and which could really open the door so our
scientists could get to work on embryonic stem cell research.
It seems--I am not accusing anyone of this, but it is the process we
go through sometimes--there is a lot of smoke and mirrors going on, and
a lot of bills are popping up to confuse the issue and to try to pull
people away from support of H.R. 810.
Again, I say to my friend from Tennessee, I hope that we can have
some assurance from the leader that when we get back in September that
we will take up H.R. 810 and, I say to the Senator from Tennessee, if
they want to bring up these other bills at some other time, in some
other context, I can assure him this Senator would not object. I would
have no objection to it. But right now there are objections to bringing
them up at the same time, not just on this side of the aisle, but I
also understand on the other side of the aisle.
It seems to me the clearest way is to bring up H.R. 810 and the cord
blood bill and get them out of the way and deal with the others. I hope
the majority leader will assure us we will do that when we come back in
September.
Mr. FRIST. To complete this, from my standpoint, I want it to be very
clear, to be understood that the majority leader of the Senate has
offered to his colleagues to bring up six bills. The statement is made
this is going to have an overwhelming bipartisan support. It did in the
House. All I am saying is, let's, in a short period of time--what has
been offered to both sides, is spend a day debating these six bills
which do, if you look at the six bills, take the range of ethical
considerations and moral considerations of this body and do look at the
science--alternative ways of developing embryonic stem cells--and let's
take them to the floor and allow each one to get a vote, and let's see
where the votes are.
It may be the bill of my distinguished colleague from Iowa will get a
majority vote or a supermajority vote, but so may the cord blood bill.
I hope it does. I think it will save lives. The alternative bill, let's
see what it is. It has never been discussed on the floor. I would hope
the distinguished colleague from Iowa would vote for it because there
is potential hope there, as well as obtaining embryonic stem cells from
embryos. Also, the cloning bill. Let's debate it in a defined period of
time and vote on that. Let's see where the body is. That has been my
approach, and that has been the offer to both sides.
The Senator is correct, on both sides of the aisle there is this
hesitation to do it. I need for my colleagues to understand that I am
pushing for clean votes over a period of time, where we can address the
very issues my two colleagues want to address.
Mr. HARKIN. I thank the Senator.
Mr. KENNEDY. Mr. President, I join my colleagues in expressing my
deep sorrow and regret that the Republican leadership has allowed
another month to go by without taking action on the bipartisan stem
cell bill approved overwhelmingly by the House of Representatives.
Over the last several weeks, Republican leaders in the Senate have
ignored the true priorities of the American people. They have denied
the Senate the opportunity to provide our troops the protections they
need against attack. They have denied the Senate the chance to
guarantee funding for veterans' health, and to raise the minimum wage,
and to allow importation of lower cost medicine from Canada and other
nations.
And they have stalled and delayed, and twisted and turned, to deny
action on legislation to unlock the healing potential of stem cell
research.
They say there is no time for stem cells, or for the needs of our
troops, or our veterans, or working families. There's plenty of time to
protect the
[[Page S9207]]
makers of lethal assault weapons--but no time for lifesaving cures.
The bill is right there, Mr. President, right there on that desk in
front of you. At any time, the majority leader could walk over, pick it
up and have a vote on a bill that would bring new hope to millions of
Americans.
For years, patients and their families waited for a medical
breakthrough to provide new hope for serious illnesses like Parkinson's
disease, spinal injury, and Alzheimer's disease.
Then at last, dedicated scientists made that breakthrough. They
discovered stem cells, which can repair the injuries that cause untold
suffering and shorten lives.
The cruel irony is that just as medicine was giving patients new
hope, the Bush administration snatched it away through needless
restrictions on stem cell research,
In a few days, on August 9, patients across America will mark the
fourth tragic anniversary of that cruel decision.
We in the United States Senate had the opportunity--no, we had the
responsibility--to see that August 9 of this year did not mark 4 years
of failure and 4 years of missed opportunity.
But the Republican leadership would not let us meet that
responsibility. They let the first week of July slip by, and then the
second, and now the last--all with no action on this urgently needed
legislation.
Every day that we delay is another day of falling behind in the race
to cure diabetes, cancer, Parkinson's disease, and many other serious
illnesses.
It is another day for America to lose ground to Korea, Singapore,
Britain, and other nations in the competition for global leadership in
biotechnology.
Most of all, it is another day of shattered hopes for millions of
patients and their families across America.
Some respond to the failure of the current policy by saying we should
explore new ways to develop embryonic stem cells. I agree. Let's
explore the potential of new discoveries in genetics and cell science
to improve the ways we can tap the potential of stem cells. But let's
not restrict essential research while scientists explore speculative
and preliminary theories.
Some say we should encourage research on stem cells from the blood in
umbilical cords or on adult stem cells from bone marrow and other
tissues. Again, I agree. We should seek help for patients wherever it
may be found. But it makes no sense to limit medical research to one
narrow channel when the Nation's leading scientists agree that these
alternatives have a more limited potential than embryonic stem cells.
As a letter signed by 80 Nobel laureates in February 2001 stated:
Current evidence suggests that adult stem cells have
markedly restricted differentiation potential. Therefore, for
disorders that prove not to be treatable with adult stem
cells, impeding human pluripotent stem cell research risks
unnecessary delay for millions of patients who may die or
endure needless suffering while the effectiveness of adult
stem cells is evaluated.
The conclusion of an NIH report in June 2001 is clear:
Stem cells in adult tissues do not appear to have the same capacity
to differentiate as do embryonic stem cells.
It would be cruel to base the hopes of millions of patients on an
ideological conclusion that these experts are wrong. By all means,
let's pursue vigorous research on adult stem cells, but let's not
deceive the American public into thinking it's an adequate substitute
for embryonic stem cell research.
Legislation should be an expression of our values, and our
legislation says loud and clear that we value patients and their
families--not rigid ideology.
It is a travesty that no action has been taken on this lifesaving
measure.
Mrs. FEINSTEIN. Mr. President, I rise to speak in support of the
unanimous consent request offered today by Senator Reid. The Senator
has asked unanimous consent for the Senate to take up H.R. 810, the
Stem Cell Research Enhancement Act, and S. 1317, the Bone Marrow and
Cord Blood Therapy and Research Act.
Both of these bills have been passed by the House and are sitting at
the desk waiting to be passed by the Senate and sent to the President
for his signature.
The month of July has come and is nearly gone. Yet these two House-
passed bills, with strong bipartisan support, sit and wait at the desk.
The Stem Cell Research Enhancement Act has 41 sponsors--Republicans
and Democrats alike. This legislation is the result of many years of
bipartisan cooperation in both the House and Senate. I am pleased to
join my colleagues, Senator Arlen Specter, Tom Harkin, Orrin Hatch, Ted
Kennedy, and Gordon Smith, who have worked tirelessly on behalf of
patients and their families across this Nation to see that embryonic
stem cell research moves forward.
This legislation is proof positive that Senators from many different
points of view, be they liberal or conservative, pro-life or pro-
choice, can work together on legislation that will help speed the pace
of cures and treatments for more than 110 million Americans.
Identical legislation passed the House on May 24 by a vote of 238 to
194. Congressman Mike Castle, Republican, Delaware, and Diana DeGette,
Democrat, Colorado, are to be commended for their tireless work in
getting this bill passed in the House.
It is essential that the Senate move quickly to pass this bill. The
clock is ticking. August 9 marks the fourth anniversary of President
Bush's policy limiting Federal funding for embryonic stem cell
research. At the time it was thought there were 78 stem cell lines
available to researchers, today that number is 22. And all 22 of the
lines available are contaminated by mouse feeder cells and not usable
for research in humans.
So why has the Senate still not acted? The simple unanimous consent
request put forth by Senator Reid would allow the Senate to vote on
this bill as early as today. We could send it to the President for his
signature tonight.
What is going on here is an attempt to obscure what is a very simple
issue. What is going on here is an attempt to allow votes on other
bills in order to pull votes away from H.R. 810, the Stem Cell Research
Enhancement Act.
I think it is appropriate for the Senate to debate other related
issues at a later time. In fact, yesterday I introduced S. 1520, the
Human Cloning Ban Act--with 25 bipartisan cosponsors--which would
prohibit once and for all the immoral and unethical act of human
reproductive cloning. I believe strongly that Congress must pass a
prohibition on human cloning or attempts to clone human beings.
But first we must act on the unanimous consent request offered today
by Senator Reid, and I hope that request will be one of the first
issues the Senate deals with after the August recess.
Embryonic stem cell research is the bright new frontier of medicine.
We owe it to the 110 million Americans suffering daily with
debilitating and catastrophic diseases to pass H.R. 810.
____________________